The US Food and Drug Administration (FDA) on Friday approved Litfulo (ritlecitinib), a once-daily oral treatment, for individuals aged 12 years and older with severe alopecia areata.
The drug was developed by US pharma giant Pfizer (NYSE: PFE), which claims it is the first and only treatment approved by the FDA for adolescents (12+) with severe alopecia areata.
However, Eli Lilly (NYSE: LLY) and Incyte (Nasdaq: INCY) in 2021 claimed the first pivotal win for a JAK inhibitor in alopecia in adults - Olumiant (baricitinib), which went on to win FDA approval in June last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze